<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101505086</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36963</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Transl Med</journal-id>
<journal-title-group>
<journal-title>Science translational medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1946-6234</issn>
<issn pub-type="epub">1946-6242</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28835516</article-id>
<article-id pub-id-type="pmc">5736385</article-id>
<article-id pub-id-type="doi">10.1126/scitranslmed.aaf7588</article-id>
<article-id pub-id-type="manuscript">NIHMS927051</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An RNA Interference Screen Identifies Druggable Regulators of MeCP2 Stability</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lombardi</surname>
<given-names>Laura M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaghlula</surname>
<given-names>Manar</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sztainberg</surname>
<given-names>Yehezkel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baker</surname>
<given-names>Steven A.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klisch</surname>
<given-names>Tiemo J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Amy A.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Eric J.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zoghbi</surname>
<given-names>Huda Y.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA</aff>
<aff id="A2">
<label>2</label>Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, TX 77030, USA</aff>
<aff id="A3">
<label>3</label>Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030, USA</aff>
<aff id="A4">
<label>4</label>Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA</aff>
<aff id="A5">
<label>5</label>Department of Pathology, Stanford University, Palo Alto, CA 94305, USA</aff>
<aff id="A6">
<label>6</label>Department of Pathology, University of California, San Francisco, San Francisco, CA 94158, USA</aff>
<aff id="A7">
<label>7</label>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA</aff>
<aff id="A8">
<label>8</label>Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence and requests for materials should be addressed to H.Y.Z. (<email>hzoghbi@bcm.edu</email>)</corresp>
<fn fn-type="COI-statement" id="FN3">
<p><bold>Competing interests</bold> The authors declare no competing financial interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>23</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>9</volume>
<issue>404</issue>
<elocation-id>eaaf7588</elocation-id>
<abstract>
<p id="P1">Alterations in gene dosage due to copy-number variation (CNV) are associated with autism spectrum disorder (ASD), intellectual disability (ID) and other psychiatric disorders. The nervous system is so acutely sensitive to the dose of methyl-CpG-binding protein 2 (MeCP2) that even a two-fold change in MeCP2 protein level—either increased or decreased—results in distinct disorders with overlapping features including ID, autistic behavior and severe motor dysfunction. Rett syndrome is caused by loss-of-function mutations in <italic>MECP2</italic>, whereas duplications spanning the <italic>MECP2</italic> locus result in <italic>MECP2</italic> Duplication Syndrome (MDS) which accounts for ~1% of X-linked ID. Despite evidence from mouse models that restoring MeCP2 levels can reverse the course of disease, there are currently no FDA-approved therapies available to clinically modulate MeCP2 abundance. In this study we used a forward genetic screen against all known human kinases and phosphatases to identify druggable regulators of MeCP2 stability. Two putative modulators of MeCP2 levels, HIPK2 and protein phosphatase PP2A, were validated as stabilizers of MeCP2 <italic>in vivo</italic>. Further, pharmacological inhibition of PP2A <italic>in vivo</italic> reduced MeCP2 levels within the nervous system and rescued both overexpression and motor abnormalities in a mouse model of MDS. Our findings reveal potential therapeutic targets for treating disorders of altered <italic>MECP2</italic> dosage and establish a potent strategy to identify druggable candidates for the broader category of neurologic disease resulting from CNVs.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>